Comparison of efficacy of low- (80 mg/day) and high- (160-320 mg/day) dose valsartan in the prevention of in-stent restenosis after implantation of bare-metal stents in type B2/C coronary artery lesions

American Journal of Cardiovascular Drugs

Volumn 8, Issue 2, 2008, Pages 83-87

  Peters, Stefan ^a,b  

^a University Hospital of Magdeburg   (Germany)

^b Klinikum Quedlinburg   (Germany)

Author keywords

Angiotensin II 1 receptor antagonists, therapeutic use; Coronary stenting; Restenosis, prevention; Stent thrombosis, prevention; Valsartan, therapeutic use

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; FLUINDOSTATIN; VALSARTAN;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY STENT; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HEART INFARCTION; HUMAN; HYPOTENSION; KIDNEY FAILURE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RESTENOSIS; REVASCULARIZATION; SEX DIFFERENCE; SIDE EFFECT; THROMBOSIS;

EID: 42449155997     PISSN: 11753277     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03256585     Document Type: Article

References (21)

1. Peters S, Götting B, Trümmel M, et al. Valsartan for the prevention of restenosis after stenting of type B2/C lesions: the Val-PREST trial. J Invasive Cardiol 2001; 13: 93-7
2. Peters S, Trümmel M, Meyners W, et al. Valsartan versus ACE inhibition after bare metal stent implantation: results of the VALVACE trial. Int J Cardiol 2005; 98: 331-5
3. Radke PW, Figulla HR, Drexler H, et al., for the AACHEN Trial Investigators. A double-blind, randomized, placebo-controlled multicenter clinical trial to evaluate the effects of the angiotensin II receptor blocker candesartan cilexetil on intimal hyperplasia after coronary stent implantation. Am Heart J 2006; 152: 761.e1-6
4. Iwata A, Miura S, Imaizumi S, et al. Do valsartan and losartan have the same effects in the treatment of coronary artery disease? Circ J 2007; 71: 31-8
5. Schachner T, Oberhuber A, Zou Y, et al. Rapamycin treatment is associated with an increased apoptosis rate in experimental vein grafts. Eur J Cardiothorac Surg 2005; 27: 302-6
6. Guerin P, Sauzeau V, Rolli-Derkinderen M, et al. Stent implantation activates RhoA in human arteries: inhibitory effect of rapamycin. J Vasc Res 2005; 42: 21-8
7. Barker TA, Massett MP, Korshunov VA, et al. Angiotensin II type 2 receptor expression after vascular injury: differing effects of angiotensin-converting enzyme inhibition and angiotensin receptor blockade. Hypertension 2006; 48: 942-9
8. Cohn JN, Anand IS, Latini R, et al., on behalf of the Valsartan Heart Failure Trial Investigators. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial. Circulation 2003; 108: 1306-9
9. Matsuo Y, Imanishi T, Hayashi Y, et al. The effect of senescence of endothelial progenitor cells on in-stent restenosis in patients undergoing coronary stenting. Intern Med 2006; 45: 581-7
10. Bahlmann FH, de Groot K, Mueller O, et al. Stimulation of endothelial progenitor cells: new putative therapeutic effect of angiotensin II receptor antagonists. Hypertension 2005; 45: 526-9
11. Sketch Jr MH, Ball M, Rutherford B, et al., for the Driver Investigators. Evaluation of the Medtronic (Driver) cobalt-chromium alloy coronary stent system. Am J Cardiol 2005; 95: 8-12
12. Legrand V, Kelbaek H, Hauptmann KE, et al., on behalf of the CLASS Investigators. Clinical and angiographic analysis with a cobalt alloy coronary stent (Driver) in stable and unstable angina pectoris. Am J Cardiol 2006; 97: 349-52
13. Bonnier HJRM, van den Heuvel P, Legrand V, et al. Clinical and angiographic outcomes after Tsunami coronary stent placement. J Invas Cardiol 2004; 16: 252-6
14. Danzi GB, Capuano C, Sesana M, et al. Six-month clinical and angiographic outcomes of the Tecnic Carbostent coronary system: the Phantom IV study. J Invas Cardiol 2004; 16: 641-4
15. Kaiser C, Brunner-La Rocca HP, Buser PT, et al., on behalf of the BASKET Investigators. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: randomised Basel Stent Kosten Effektivitäts Trial (BASKET). Lancet 2005; 366: 921-9
16. Amano T, Matsubara T, Izana H, et al. Impact of plasma aldosterone levels for prediction of in-stent restenosis. Am J Cardiol 2006; 97: 785-8
17. McKelvie RS, Yusuf S, Pericak D, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Circulation 1999; 100: 1056-64
18. Wolf G, Ziyadeh FN, Thaiss F, et al. Angiotensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells: role of the angiotensin type 2 receptor. J Clin Invest 1997; 100: 1047-58
19. Kim MP, Zhou M, Wahl LM. Angiotensin II increases human monocyte matrix metalloproteinase-1 through the AT2 receptor and prostaglandin E2: implications for atherosclerotic plaque rupture. J Leukoc Biol 2005; 78: 195-201
20. Okumura M, Iwai M, Ide A, et al. Sex difference in vascular injury and the vasoprotective effect of valsartan are related to differential AT2 receptor expression. Hypertension 2005; 46: 577-83
21. Nickenig G, Baumer AT, Grohe C, et al. Estrogen modulates AT1 receptor gene expression in vitro and in vivo. Circulation 1998; 97: 2197-201